A Phase 3 interventional study of Ceftazidime-avibactam and metronidazole in Complicated Intra-abdominal Infection, sponsored by Pfizer. Completed at 30 sites in 3 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2017-09-06.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Intraabdominal Infections by Pfizer — none open to participants now, none under way, none of them phase 3. Intraabdominal Infections · Pfizer.
Among the 19 studies in Intraabdominal Infections by Pfizer, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2013, is one of 5 in phase 3, and was the 13th registered.
129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.
Browse Intraabdominal Infections studies →None of the 19 studies in Intraabdominal Infections by Pfizer is open now. The open studies under Intraabdominal Infections, anywhere →
Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 486 is above the median of 140 across 77 interventional studies indexed under Intraabdominal Infections.
Median enrollment 144 across the 14 interventional studies, 203 across the 5 observational. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Intraabdominal Infections by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ceftazidime-avibactam · Drug: metronidazole
Drug: Meropenem
Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg
Metronidazole 500mg/100ml solution for infusion
Meropenem powder for solution for infusion 1000mg
The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Clinically Evaluable (CE) Analysis Set.
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: At the test of cure visit (Day 28 to35)
The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)
The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: At the test of cure (TOC) (Day 28 to 35)
The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: At the late follow up (LFU) (Day 42 to 49)
The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)
The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: At the test of cure (TOC) (Day 28 to 35)
The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: At the late follow up (LFU) (Day 42 to 49)
The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)
The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: At the test of cure (TOC) (Day 28 to 35)
The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: At the late follow up (LFU) (Day 42 to 49)
The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Clinically Evaluable (CE) Analysis Set.
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)
The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Clinically Evaluable (CE) Analysis Set.
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
Time frame: At late follow up (LFU) visits (Day 42 to 49)
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
Time frame: At the test of cure (TOC) (Day 28 to 35)
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
Time frame: At the late follow up (LFU) (Day 42 to 49)
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
Time frame: At the test of cure (TOC) (Day 28 to 35)
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
Time frame: At the late follow up (LFU) (Day 42 to 49)
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
Time frame: At the test of cure (TOC) (Day 28 to 35)
The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
Time frame: At the late follow up (LFU) (Day 42 to 49)
The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)
The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
Time frame: At the test of cure (TOC) (Day 28 to 35)
The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
Time frame: At the late follow up (LFU) (Day 42 to 49)
The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)
The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
Time frame: At the test of cure (TOC) (Day 28 to 35)
The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
Time frame: At the late follow up (LFU) (Day 42 to 49)
The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
Time frame: At the end of treatment (EOT) (within 24 hours after last IV dose)
The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable(ME) Analysis Set.
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
Time frame: At the test of cure (TOC) (Day 28 to 35)
The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
Time frame: At the late follow up (LFU) (Day 42 to 49)
The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
The microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).
Time frame: At the test of cure (TOC) (Day 28 to 35)
The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiologically Evaluable (ME) Analysis Set.
The microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).
Time frame: At the test of cure (TOC) (Day 28 to 35)
The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Extended Microbiologically Evaluable (ME) Analysis Set.
The microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).
Time frame: At the test of cure (TOC) (Day 28 to 35)
The Time to First Defervescence in the Clinically Evaluable (CE) Analysis Set for Patients Who Have Fever at Study Entry.
Time to first defervescence was calculated for patients with a fever (\>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day. Time to first defervescence while on IV study therapy in the CE analysis set at TOC for patients who had fever at study entry is defined as time (in days) from the first dose of IV study therapy to first absence of fever.
Time frame: while on study therapy (from Day 1 to Day 14)
The Time to First Defervescence in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set for Patients Who Have Fever at Study Entry.
Time to first defervescence was calculated for patients with a fever (\>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day. Time to first defervescence while on IV study therapy in the CE analysis set at TOC for patients who had fever at study entry is defined as time (in days) from the first dose of IV study therapy to first absence of fever.
Time frame: while on study therapy (from Day 1 to Day 14)
Safety and Tolerability by Incidence and Severity of Adverse Events and Serious Adverse Events and Mortality.
Adverse event data were collected from the screening/consent visit until the late follow-up visit (i.e. Day -1/0 to Day 42).
Time frame: study duration (from screening to Day 49 LFU visit)
Safety and Tolerability by Incidence: Extent of Exposure.
Duration of exposure is calculated as the difference between the last study therapy date and the first study therapy date converted to days plus 1 day. Actual calculated duration could be shorter or longer than a full day.
Time frame: study duration (from screening to Day 49 LFU visit)
Safety and Tolerability: Clinical Laboratory Evaluation Hematology.
Potentially clinically significant (PCS) post Baseline hematology values up to LFU (Safety analysis set)
Time frame: study duration (from screening to Day 49 LFU visit)
Safety and Tolerability: Clinical Laboratory Evaluation Clinical Chemistry.
Potentially clinically significant (PCS) post Baseline clinical chemistry values up to LFU (Safety analysis set)
Time frame: study duration (from screening to Day 49 LFU visit)
Safety and Tolerability:ECG , QTcB and QTcF Intervals
Shifts in ECG interpretation and changes in QT, QTcB, and QTcF intervals , from baseline to post baseline.
Time frame: EOT visit/any observation on treatment
Plasma Concentrations for Ceftazidime and Avibactam
Blood samples were taken from all patients on Day 3 for the pharmacokinetic evaluation of ceftazidime and avibactam plasma concentrations
Time frame: At Day 3: Anytime within 15 minutes prior to or after stopping study drug, anytime between 30 and 90 minutes after stopping study drug, anytime between 300 minutes and 360 minutes after stopping study drug.
Overall, 486 patients were enrolled from 43 centers in 3 countries in this study. The first patient was enrolled on 14 January 2013 and the last patient last visit was on 14 March 2015.
| Milestone | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Started | 219 | 222 |
| Completed | 190 | 196 |
| Not completed | 29 | 26 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Lost to follow-up | 5 | 10 |
| Withdrew: Other eligibility criteria | 7 | 7 |
| Withdrew: Withdrawal by subject | 16 | 8 |
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 166 | 173 |
| Clinical failure | 11 | 11 |
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 103 | 113 |
| Clinical failure | 3 | 5 |
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 92 | 107 |
| Clinical failure | 7 | 6 |
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 89 | 100 |
| Clinical failure | 7 | 6 |
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 104 | 120 |
| Clinical failure | 3 | 5 |
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 93 | 113 |
| Clinical failure | 7 | 6 |
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 90 | 106 |
| Clinical failure | 7 | 6 |
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 126 | 140 |
| Clinical failure | 6 | 7 |
| Indeterminate | 11 | 5 |
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 119 | 135 |
| Clinical failure | 10 | 9 |
| Indeterminate | 14 | 8 |
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 116 | 132 |
| Clinical failure | 10 | 9 |
| Indeterminate | 17 | 11 |
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 183 | 187 |
| Clinical failure | 7 | 9 |
The proportion of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Clinical cure | 157 | 168 |
| Clinical failure | 11 | 11 |
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Favorable | 103 | 113 |
| Unfavorable | 3 | 5 |
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Favorable | 92 | 107 |
| Unfavorable | 7 | 6 |
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Favorable | 89 | 100 |
| Unfavorable | 7 | 6 |
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Favorable | 104 | 120 |
| Unfavorable | 3 | 5 |
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Favorable | 93 | 113 |
| Unfavorable | 7 | 6 |
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Favorable | 90 | 106 |
| Unfavorable | 7 | 6 |
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Favorable | 126 | 140 |
| Unfavorable | 6 | 7 |
| Indeterminate | 11 | 5 |
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Favorable | 119 | 135 |
| Unfavorable | 10 | 9 |
| Indeterminate | 14 | 8 |
Per-patient "favorable" response indicates that all of the patient's baseline pathogens are "eradicated" or "presumed eradicated".
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Favorable | 116 | 132 |
| Unfavorable | 10 | 9 |
| Indeterminate | 17 | 11 |
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
| Participants with favorable responses | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Escherichia coli (n=84, 89) | 77 | 86 |
| Klebsiella oxytoca (n=5, 5) | 5 | 5 |
| Klebsiella pneumoniae (n=28,35) | 22 | 32 |
| Pseudomonas aeruginosa (n=17, 20) | 15 | 17 |
| Streptococcus anginosus grou (n=8, 7) | 7 | 6 |
| Streptococcus mitis group (n=6, 5) | 6 | 5 |
| Enterococcus faecalis (n=6, 6) | 5 | 5 |
| Enterococcus faecium (n=4, 7) | 4 | 5 |
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
| Participants with favorable responses | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Escherichia coli (n=84, 89) | 70 | 84 |
| Klebsiella oxytoca (n=5, 5) | 5 | 5 |
| Klebsiella pneumoniae (n=28,35) | 23 | 31 |
| Pseudomonas aeruginosa (n=17, 20) | 14 | 17 |
| Streptococcus anginosus group (n=8, 7) | 7 | 5 |
| Streptococcus mitis group (n=6, 5) | 6 | 5 |
| Enterococcus faecalis (n=6, 6) | 6 | 4 |
| Enterococcus faecium (n=4, 7) | 4 | 5 |
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
| Participants with favorable responses | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Escherichia coli (n=84, 89) | 70 | 82 |
| Klebsiella pneumoniae (n=28, 35) | 22 | 31 |
| Pseudomonas aeruginosa (n=17, 20) | 14 | 17 |
| Klebsiella oxytoca (n=5, 5) | 4 | 5 |
| Enterococcus faecalis (n=6, 6) | 4 | 4 |
| Enterococcus faecium (n=4, 7) | 3 | 5 |
| Streptococcus anginosus group (n=8, 7) | 7 | 5 |
| Streptococcus mitis group (n=6, 5) | 6 | 5 |
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
| Participants with favorable responses | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Escherichia coli (n=69, 77) | 68 | 75 |
| Klebsiella oxytoca (n=5, 5) | 5 | 5 |
| Klebsiella pneumoniae (n=22, 29) | 21 | 28 |
| Pseudomonas aeruginosa (n=14, 16) | 14 | 14 |
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
| Participants with favorable responses | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Escherichia coli (n=69, 77) | 64 | 74 |
| Klebsiella oxytoca (n=5, 5) | 5 | 5 |
| Klebsiella pneumoniae (n=22, 29) | 21 | 28 |
| Pseudomonas aeruginosa (n=14, 16) | 13 | 14 |
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
| Participants with favorable responses | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Escherichia coli (n=69, 77) | 63 | 72 |
| Klebsiella oxytoca (n=5, 5) | 4 | 5 |
| Klebsiella pneumoniae (n=22, 29) | 21 | 27 |
| Pseudomonas aeruginosa (n=14, 16) | 13 | 14 |
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
| Participants with favorable responses | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Escherichia coli (n=70, 80) | 69 | 78 |
| Klebsiella oxytoca (n=5, 5) | 5 | 5 |
| Klebsiella pneumoniae (n=22, 30) | 21 | 29 |
| Pseudomonas aeruginosa (n=14, 18) | 14 | 16 |
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
| Participants with favorable responses | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Escherichia coli (n=70, 80) | 65 | 77 |
| Klebsiella oxytoca (n=5, 5) | 5 | 5 |
| Klebsiella pneumoniae (n=22, 30) | 21 | 29 |
| Pseudomonas aeruginosa (n=14, 18) | 13 | 16 |
The proportion of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.
| Participants with favorable responses | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Escherichia coli (n=70, 80) | 64 | 75 |
| Klebsiella oxytoca (n=5, 5) | 4 | 5 |
| Klebsiella pneumoniae (n=22, 30) | 21 | 28 |
| Pseudomonas aeruginosa (n=14, 18) | 13 | 16 |
The microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Favorable | 24 | 27 |
| Unfavorable | 1 | 1 |
| Indeterminate | 4 | 1 |
The microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Favorable | 22 | 23 |
| Unfavorable | 1 | 1 |
The microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Favorable | 22 | 25 |
| Unfavorable | 1 | 1 |
Time to first defervescence was calculated for patients with a fever (\>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day. Time to first defervescence while on IV study therapy in the CE analysis set at TOC for patients who had fever at study entry is defined as time (in days) from the first dose of IV study therapy to first absence of fever.
| Days | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| The Time to First Defervescence in the Clinically Evaluable (CE) Analysis Set for Patients Who Have Fever at Study Entry. | 1 (1 to 5) | 1.5 (1 to 4) |
Time to first defervescence was calculated for patients with a fever (\>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day. Time to first defervescence while on IV study therapy in the CE analysis set at TOC for patients who had fever at study entry is defined as time (in days) from the first dose of IV study therapy to first absence of fever.
| Days | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| The Time to First Defervescence in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set for Patients Who Have Fever at Study Entry. | 1 (1 to 5) | 2 (1 to 4) |
Adverse event data were collected from the screening/consent visit until the late follow-up visit (i.e. Day -1/0 to Day 42).
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Any AE | 82 | 83 |
| Any SAE | 9 | 11 |
| Any AE leading to discontinuation of IP | 7 | 3 |
| Any AE of severe intensity | 5 | 5 |
| Total number of deaths | 2 | 1 |
| Deaths due to disease progression | 2 | 0 |
| Any AE with outcome=death | 0 | 1 |
Duration of exposure is calculated as the difference between the last study therapy date and the first study therapy date converted to days plus 1 day. Actual calculated duration could be shorter or longer than a full day.
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| 1 - 2 days | 10 | 5 |
| 3 - 4 days | 6 | 5 |
| 5 -10 days | 175 | 181 |
| 11 - 14 days | 24 | 26 |
| >14 days | 0 | 0 |
Potentially clinically significant (PCS) post Baseline hematology values up to LFU (Safety analysis set)
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Platelet count: PCS (Low) | 1 | 1 |
| Platelet count: PCS (High) | 5 | 4 |
| Red blood cell count: PCS (Low) | 7 | 13 |
| Red blood cell count: PCS (High) | 0 | 0 |
| White blood cell: PCS (Low) | 1 | 1 |
| White blood cell: PCS (High) | 4 | 5 |
| Hemoglobin: PCS (Low) | 7 | 14 |
| Hemoglobin: PCS (High) | 0 | 0 |
| Lymphocytes: PCS (Low) | 1 | 1 |
| Lymphocytes: PCS (High) | 0 | 1 |
| Neutrophils: PCS (Low) | 4 | 2 |
| Neutrophils: PCS (High) | 9 | 8 |
| Eosinophils: PCS (High) | 0 | 0 |
| Monocytes: PCS (High) | 0 | 0 |
| Basophils: PCS (High) | 0 | 0 |
| Direct Coombs test:- at Baseline, + post-Baseline | 15 | 2 |
| Hematocrit (ratio): PCS (Low) | 5 | 8 |
| Hematocrit (ratio): PCS (High) | 0 | 0 |
Potentially clinically significant (PCS) post Baseline clinical chemistry values up to LFU (Safety analysis set)
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Alanine aminotransferase (μkat/L): PCS (High) | 3 | 8 |
| Alkaline phosphatase (μkat/L): PCS (Low) | 0 | 0 |
| Alkaline phosphatase (μkat/L): PCS (High) | 2 | 3 |
| Aspartate aminotransferase (μkat/L): PCS (High) | 4 | 4 |
| Bicarbonate (mmol/L) PCS (Low) | 1 | 0 |
| Bicarbonate (mmol/L): PCS (High) | 0 | 0 |
| Creatinine (μmol/L): PCS (High) | 0 | 1 |
| Glucose (non-fasting) (mmol/L): PCS (Low) | 0 | 0 |
| Glucose (non-fasting) (mmol/L): PCS (High) | 1 | 1 |
| Gamma-glutamyl transferase (μkat/L):PCS (High) | 2 | 4 |
| Inorganic phosphorus (mmol/L): PCS (Low) | 3 | 7 |
| Inorganic phosphorus (mmol/L): PCS (High) | 0 | 0 |
| Potassium (mmol/L): PCS (Low) | 9 | 5 |
| Potassium (mmol/L): PCS (High) | 3 | 1 |
| Total bilirubin (μmol/L): PCS (High) | 0 | 1 |
| Direct bilirubin (μmol/L): PCS (High) | 1 | 1 |
Shifts in ECG interpretation and changes in QT, QTcB, and QTcF intervals , from baseline to post baseline.
| Number of patients | Ceftazidime-Avibactam Plus Metronidazole | Meropenem |
|---|---|---|
| Normal to Abnormal: EOT | 17 | 14 |
| Normal to Abnormal: Anytime up to EOT | 34 | 30 |
| Reaching a value in QT: ≥450 (ms) | 9 | 10 |
| Reaching a value in QT: ≥480 (ms) | 2 | 1 |
| Reaching a value in QT: ≥500 (ms) | 0 | 0 |
| QT: ≥500 and increase from Baseline ≥60(ms) | 0 | 0 |
| Increase in QT: ≥30 (ms) | 115 | 114 |
| Increase in QT: ≥60 (ms) | 50 | 44 |
| Decrease in QT: ≥30 (ms) | 24 | 24 |
| Decrease in QT: ≥60 (ms) | 12 | 4 |
| Reaching a value in QTcB: ≥450(ms) | 57 | 63 |
| Reaching a value in QTcB: ≥480(ms) | 13 | 8 |
| Reaching a value in QTcB: ≥500 (ms) | 4 | 2 |
| QTcB: ≥500 and increase from Baseline ≥60(ms) | 2 | 1 |
| Increase in QTcB: ≥30 (ms) | 21 | 27 |
| Increase in QTcB: ≥60 (ms) | 2 | 1 |
| Decrease in QTcB: ≥30 (ms) | 42 | 26 |
| Decrease in QTcB: ≥60 (ms) | 6 | 4 |
| Reaching a value in QTcF: ≥450 (ms) | 19 | 18 |
| Reaching a value in QTcF: ≥480 (ms) | 4 | 0 |
| Reaching a value in QTcF: ≥500 (ms) | 1 | 0 |
| QTcF: ≥500 and increase from Baseline ≥60 (ms) | 0 | 0 |
| Increase in QTcF: ≥30 (ms) | 42 | 41 |
| Increase in QTcF: ≥60 (ms) | 4 | 3 |
| Decrease QTcF: ≥30 (ms) | 21 | 19 |
| Decrease QTcF: ≥60 (ms) | 7 | 1 |
Blood samples were taken from all patients on Day 3 for the pharmacokinetic evaluation of ceftazidime and avibactam plasma concentrations
| ng/mL | Ceftazidime(1) | Avibactam(1) | Ceftazidime(2) | Avibactam(2) | Ceftazidime(3) | Avibactam(3) |
|---|---|---|---|---|---|---|
| Plasma Concentrations for Ceftazidime and Avibactam | 60300.4 (1390 to 1880000) | 10126.9 (197 to 435000) | 46473.9 (2080 to 210000) | 7289.3 (229 to 36300) | 9555.0 (1740 to 222000) | 1207.2 (227 to 36300) |
Collected over Adverse event data were collected from the screening/consent visit until the late follow-up visit (i.e. Day -1/0 to Day 42). FOR SAE's - only those reported by 2 or more patients in either group are shown in this summary.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CAZ-AVI Plus Metronidazole | — | 9/215 (4.2%) | 44/215 (20.5%) |
| Meropenem | — | 11/217 (5.1%) | 47/217 (21.7%) |
| Event | CAZ-AVI Plus Metronidazole | Meropenem |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/215 | 0/217 |
| Arteriosclerosis coronary arteryCardiac disorders | 1/215 | 0/217 |
| Abdominal pain lowerGastrointestinal disorders | 1/215 | 0/217 |
| GastritisGastrointestinal disorders | 1/215 | 0/217 |
| Cholangitis acuteHepatobiliary disorders | 1/215 | 0/217 |
| Hepatic function abnormalHepatobiliary disorders | 1/215 | 0/217 |
| Abdominal infectionInfections and infestations | 1/215 | 0/217 |
| Postoperative wound infectionInfections and infestations | 1/215 | 1/217 |
| MetastasisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/215 | 0/217 |
| Acute kidney injuryRenal and urinary disorders | 1/215 | 1/217 |
| Event | CAZ-AVI Plus Metronidazole | Meropenem |
|---|---|---|
| NauseaGastrointestinal disorders | 18/215 | 4/217 |
| DiarrhoeaGastrointestinal disorders | 13/215 | 16/217 |
| PyrexiaGeneral disorders | 9/215 | 12/217 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/215 | 8/217 |
| Hepatic function abnormalHepatobiliary disorders | 0/215 | 6/217 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 5/215 | 6/217 |
| ConstipationGastrointestinal disorders | 5/215 | 3/217 |
| VomitingGastrointestinal disorders | 5/215 | 4/217 |
| HeadacheNervous system disorders | 3/215 | 5/217 |
Baseline analysis population is MITT ; Randomized patients who received any amount of study therapy, excluding patients who received both study therapies. 9 patients were randomized but not treated, and one patient received doses of both treatments.
| Age, Continuous(Years) | Ceftazidime-Avibactam Plus Metronidazole | Meropenem | Total |
|---|---|---|---|
| Mean | 48.5 ± 16.83 | 48.5 ± 17.43 | 48.5 ± 17.11 |
| Age, Customized(Participants) | Ceftazidime-Avibactam Plus Metronidazole | Meropenem | Total |
|---|---|---|---|
| 18-45 Years | 89 | 96 | 185 |
| 46-64 Years | 85 | 72 | 157 |
| 65-74 Years | 28 | 30 | 58 |
| 75-90 Years | 12 | 19 | 31 |
| Sex: Female, Male(Participants) | Ceftazidime-Avibactam Plus Metronidazole | Meropenem | Total |
|---|---|---|---|
| Female | 73 | 64 | 137 |
| Male | 141 | 153 | 294 |
| Race/Ethnicity, Customized(Participants) | Ceftazidime-Avibactam Plus Metronidazole | Meropenem | Total |
|---|---|---|---|
| Asian | 214 | 217 | 431 |
The record gives a start of Jan 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metronidazole